News coverage about Digirad (NASDAQ:DRAD) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Digirad earned a news sentiment score of 0.10 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 47.564910838493 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Separately, ValuEngine lowered Digirad from a “buy” rating to a “hold” rating in a research note on Wednesday, May 2nd.
Shares of Digirad traded down $0.10, hitting $1.70, during trading hours on Wednesday, MarketBeat Ratings reports. The company’s stock had a trading volume of 295,706 shares, compared to its average volume of 77,809. Digirad has a 12 month low of $1.60 and a 12 month high of $1.80. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.20 and a current ratio of 1.62.
Digirad (NASDAQ:DRAD) last posted its quarterly earnings data on Tuesday, May 1st. The medical equipment provider reported ($0.07) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.01) by ($0.06). Digirad had a negative return on equity of 2.36% and a negative net margin of 25.76%. The firm had revenue of $25.47 million for the quarter.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 30th. Stockholders of record on Tuesday, May 15th will be given a $0.055 dividend. The ex-dividend date of this dividend is Monday, May 14th. This represents a $0.22 dividend on an annualized basis and a dividend yield of 12.94%.
In other news, insider Matthew G. Molchan purchased 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The stock was acquired at an average cost of $2.14 per share, with a total value of $53,500.00. Following the acquisition, the insider now owns 77,819 shares in the company, valued at approximately $166,532.66. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 9.10% of the company’s stock.
Digirad Corporation provides healthcare solutions in the United States. It operates through Diagnostic Services, Mobile Healthcare, and Diagnostic Imaging segments. The Diagnostic Services segment provides nuclear and ultrasound imaging services to physicians who perform nuclear imaging, echocardiography, vascular or general ultrasound tests, imaging systems, radiopharmaceuticals, and licensing services, as well as offers remote cardiac event monitoring services.
Receive News & Ratings for Digirad Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Digirad and related companies with MarketBeat.com's FREE daily email newsletter.